04.23.15
New research published in the journal Nutrition Research has demonstrated the clinical benefit of ACTAZIN, a green kiwifruit ingredient produced by Anagenix, Ltd for digestive health. Results from this randomized, double-blind, placebo-controlled study indicated clinically significant benefits in a healthy cohort.
The study evaluated 19 healthy adult volunteers and 9 volunteers with complaints of functional constipation for stool frequency and quality along with a daily diary for quality of life. Results demonstrated a statistically significant increase (P < 0.014) in mean daily bowel movements (healthy cohort) following one month of ACTAZIN (2,400 mg/day) consumption.
The magnitude of effect corresponded to an approximate increase of one bowel movement per week, which is regarded as a clinically meaningful effect by FDA.
A lower daily dose of ACTAZIN (600 mg) produced a numerically equivalent result, just missing statistical significance (P < 0.06) across the entire group, but was statistically significant in the responder sub-group (P < 0.005; n = 14). This suggests a low dose (600 mg) of ACTAZIN alone could help maintain a healthy digestive system.
ACTAZIN is a powdered ingredient derived from whole New Zealand green (Actinidia deliciosa “Hayward”) kiwifruit from which the skin and seeds are removed and the remaining flesh cold processed for use in dietary supplements for the support of digestive health.
Contributing to the modes of action for ACTAZIN include the presence of bioactive substances including fiber, polyphenolics and the kiwifruit-specific enzyme, actinidin. An additional mode of action may be its ability to serve as a substrate for endogenous gut bacteria.
For more information: www.StratumNutrition.com
The study evaluated 19 healthy adult volunteers and 9 volunteers with complaints of functional constipation for stool frequency and quality along with a daily diary for quality of life. Results demonstrated a statistically significant increase (P < 0.014) in mean daily bowel movements (healthy cohort) following one month of ACTAZIN (2,400 mg/day) consumption.
The magnitude of effect corresponded to an approximate increase of one bowel movement per week, which is regarded as a clinically meaningful effect by FDA.
A lower daily dose of ACTAZIN (600 mg) produced a numerically equivalent result, just missing statistical significance (P < 0.06) across the entire group, but was statistically significant in the responder sub-group (P < 0.005; n = 14). This suggests a low dose (600 mg) of ACTAZIN alone could help maintain a healthy digestive system.
ACTAZIN is a powdered ingredient derived from whole New Zealand green (Actinidia deliciosa “Hayward”) kiwifruit from which the skin and seeds are removed and the remaining flesh cold processed for use in dietary supplements for the support of digestive health.
Contributing to the modes of action for ACTAZIN include the presence of bioactive substances including fiber, polyphenolics and the kiwifruit-specific enzyme, actinidin. An additional mode of action may be its ability to serve as a substrate for endogenous gut bacteria.
For more information: www.StratumNutrition.com